Activity of deferasirox in Mucorales: Influences of species and exogenous iron

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 411-413

  Lewis, Russell E ^a,b   Pongas, Georgios N ^a   Albert, Nathaniel ^a   Ben Ami, Ronen ^a   Walsh, Thomas J ^c   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; DEFERASIROX; IRON;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CUNNINGHAMELLA BERTHOLLETIAE; DRUG ACTIVITY; FUNGAL STRAIN; MINIMUM INHIBITORY CONCENTRATION; MUCOR; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS;

ANTIFUNGAL AGENTS; BENZOIC ACIDS; IRON; MICROBIAL SENSITIVITY TESTS; MUCORALES; TRIAZOLES;

EID: 78650665671     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00792-10     Document Type: Article

References (11)

1. Boelaert, J. R., M. de Locht, and Y.-J. Schneider. 1994. The effect of deferoxamine on different zygomycetes. J. Infect. Dis. 169:231-232.
2. Boelaert, J. R., M. de Locht, J. Van Cutsem, V. Kerrels, C. B. A. Verdonck, H. W. Van Landuyt, and Y.-J. Schneider. 1993. Mucormycosi s during deferoxaminetherapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clinical Invest. 91:1979-1986.
3. Bowman, J. C., P. S. Hicks, M. B. Kurtz, H. Rosen, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition. Clinical and Laboratory Standards Institute, Wayne, PA.
5. de Locht, M., J. R. Boelaert, and Y. J. Schneider. 1994. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem. Pharmacol. 47:1843-1850.
6. Espinel-Ingroff, A. 2001. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J. Clin. Microbiol. 39:954-958.
7. Espinel-Ingroff, A., A. Fothergill, J. Peter, M. G. Rinaldi, and T. J. Walsh. 2002. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J. Clin. Microbiol. 40:3204-3208.
8. Ibrahim, A. S., T. Gebermariam, Y. Fu, L. Lin, M. I. Husseiny, S. W. French, J. Schwartz, C. D. Skory, J. E. Edwards, Jr., and B. J. Spellberg. 2007. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J. Clin. Invest. 117:2649-2657.
9. Kontoyiannis, D. P., and R. E. Lewis. 2006. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect. Dis. Clin. North Am. 20:581-607, vi.
10. Piga, A., R. Galanello, G. L. Forni, M. D. Cappellini, R. Origa, A. Zappu, G. Donato, E. Bordone, A. Lavagetto, L. Zanaboni, R. Sechaud, N. Hewson, J. M. Ford, H. Opitz, and D. Alberti. 2006. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91:873-880.
11. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.